AqT Therapeutics

AqT Therapeutics is a Toronto-based biotechnology company dedicated to developing first-in-class small molecule inhibitors of aquaporins, a family of water channel proteins essential for fluid homeostasis. The company's lead research focuses on Aquaporin-4 (AQP4), the most abundant water channel in the central nervous system, to treat chronic neuropathic pain and other neurological disorders. Spun out from the University of Toronto and the University Health Network (UHN), AqT Therapeutics leverages proprietary chemical scaffolds to modulate water transport as a novel therapeutic mechanism. Their approach aims to provide non-opioid alternatives for patients suffering from debilitating pain conditions where current treatments are often ineffective.